Results 171 to 180 of about 121,312 (312)

APOE*4 risk-modifying genes and drug targets in Alzheimer's disease through cell-type-specific genomic analyses. [PDF]

Alzheimers Dement
Zeng Y, Cook N, Yang C, Sivasankaran SK, Fujita M, Gardell ZA, Le Guen Y, Shigemizu D, Ozaki K, Morizono T, Hara N, Miyashita A, Ikeuchi T, Pottier C, Cruchaga C, Napolioni V, Corces MR, Menon V, Greicius MD, Belloy ME.   +19 more
europepmc   +1 more source

Correlational data for APOE groups.

BackgroundThe Apolipoprotein E (APOE) gene has been established in the Alzheimer’s disease (AD) literature to impact brain structure and function and may also show congruent effects in healthy older adults, although findings in this population are much ...
Theone Paterson (18404173), Colleen Lacey (18404170), Jodie R. Gawryluk (18262848)   +2 more
core   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Panax quinquefolium saponin decreases atherosclerosis in ovariectomized ApoE^-/- mice via regulating estrogen receptor α. [PDF]

Chin Med
Chen L, Shi JH, Ma XJ, Chai H, Wei KK, Yang Z, Tan Y, Huang HB, Shi DZ, Qu H.   +9 more
europepmc   +1 more source

'Introduction'

, 2017
Dublin
openaire   +1 more source

Genetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is increasingly recognized as a neurodegenerative disorder with a broad clinical spectrum and diverse biomarkers enabling early detection. α‐synuclein seed amplification assays (SAA) and genetic testing now allow identification of PD pathology in asymptomatic individuals.
Tal Weil, Anat Mirelman, Roy N. Alcalay, Nurit Omer, Penina Ponger, Avner Thaler   +5 more
wiley   +1 more source

Now is the time: the need to update guidance to expand access to <i>APOE</i> genetic testing. [PDF]

Front Dement
Uhlmann WR, Chan AK, Goldman JS.
europepmc   +1 more source

Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α‐Synuclein and Mediation of Age Effects

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Meher Lad, Mark R. Baker, Nicola Pavese   +8 more
wiley   +1 more source

The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status. [PDF]

J Prev Alzheimers Dis
Milà-Alomà M, Hausle I, Petersen KK, Thropp P, Schindler SE, Tosun D, Alzheimer’s Disease Neuroimaging Initiative.   +6 more
europepmc   +1 more source

Bürhaneddin el-Merginani'nin ''Muhtaratü'n-Nevazil''eserinin edisyon kritiği

, 2010
Burhaneddin el-Merginani'nin (511/1117-593/1197) kaleme aldığı Muhtaratu-Nevâzil adlı eseri İslam Hukuku alanında önemli bir konuma sahiptir. Bu eser hicrî beşinci ve altıncı yüzyıllarda yaşamış Belhli, Buharalı ve Semerkandlı Hanefi fakihlerin görüşlerini içermektedir.
openaire   +1 more source